Sartorius launched a rationally designed CHO host cell line developed via proteomic profiling and targeted genome editing that delivered up to two‑fold higher expression titers and up to three‑fold increased productivity in intensified perfusion and fed‑batch testing at 5 L scale. The company reported consistent product quality across IgG1/4, Fc‑fusion, and bispecific modalities and stability over 70+ generations. Sartorius framed the cell line as enabling faster, more reliable lead clone generation and improved manufacturing economics. Oscar Reif (CTO) noted high clone performance and compatibility with continuous bioprocessing trends, which could reduce time to clinic and lower cost‑of‑goods for complex biologics.